RxDoctor Payments Data

Bobby Huynh, MD

Physical Medicine & Rehabilitation · Richardson, TXNPI 1114035383

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by Bioventus LLC at 53.5% of the total. Reporting peaked in 2024 at $1,576 and has fallen 92.3% since, to $122 in 2025.

$2,915in general payments, 2019–2025

Across 65 payments — averaging $44.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bioventus LLC$2K
  • AbbVie$452
  • Scilex Pharmaceuticals Inc.$249
  • Merz North America, Inc.$163
  • Vision Quest Industries Inc.$95
  • MDD US Operations, LLC$72
  • plus $327 from 12 others
$107,886in research payments, 2019–2025

Across 20 payments — averaging $5394.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$88K
  • GSK$20K

What the payments were for

  • Food & beverage$1,43149%
  • Other$1,48551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,915 in reported general payments places this provider in the 85th percentile of 651 physical medicine & rehabilitation providers in Texas.

See all physical medicine & rehabilitation providers in Texas

Medicare billing

Part B allowed, 2024
$252,331
Medicare patients
221
Services billed
11,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina44$66,933
Lidocaine87$18,538
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen482$8,711
Xtampza ErOxycodone Myristate13$6,800
Gabapentin506$6,327
Diclofenac Sodium88$6,089
Fentanyl60$5,993
Pregabalin84$2,870
Tizanidine Hcl196$2,198
Morphine Sulfate ErMorphine Sulfate70$1,845
Tramadol Hcl316$1,717
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen59$1,219
Acetaminophen-CodeineAcetaminophen With Codeine104$1,044
Duloxetine Hcl21$733
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine11$685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$452$66,93344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 651 physical medicine & rehabilitation providers in Texas.

Other physical medicine & rehabilitation in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →